Biogen (BIIB) Other Accumulated Expenses (2009 - 2026)

Biogen has reported Other Accumulated Expenses for 18 years, with the latest figure at $2.6 billion in Q2 2026.

• On a quarterly basis, Other Accumulated Expenses fell 1.29% year-over-year to $2.6 billion in Q2 2026; TTM through Jun 2026 was $2.6 billion, a 1.29% decrease from a year earlier, with the FY2025 full-year figure at $2.8 billion, changed 0.18% from the prior year.
• Other Accumulated Expenses was $2.6 billion for Q2 2026 at Biogen, up from $2.5 billion in the prior quarter.
• The five-year high for Other Accumulated Expenses was $3.8 billion in Q3 2023, with the low at $2.2 billion in Q1 2022.
• Average Other Accumulated Expenses over 5 years is $2.7 billion, with a median of $2.6 billion recorded in 2023.
• The sharpest annual moves came in 2022 and 2024: Other Accumulated Expenses advanced 29.61% in 2022, then fell 28.22% in 2024.
• Over 5 years, Other Accumulated Expenses stood at $2.5 billion in 2022, then increased by 4.05% to $2.6 billion in 2023, then grew by 7.02% to $2.8 billion in 2024, then retreated by 0.18% to $2.8 billion in 2025, then declined by 6.29% to $2.6 billion in 2026.
• The last three Other Accumulated Expenses figures came in at $2.6 billion (Q2 2026), $2.5 billion (Q1 2026), and $2.8 billion (Q4 2025), per Business Quant data.